Recent 8-K filings for OMER

• May 13, 2026, 4:06 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Omeros Q1 net income $56.1M on $73.1M non-cash gain; YARTEMLEA net sales $9.9M

  GAAP net income $56.1M ($0.78/share) vs. net loss $33.5M ($0.58) in Q1 2025; includes $73.1M non-cash gain on embedded derivatives.

• March 31, 2026, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases

  Omeros posts Q4 net income of $86.5M; YARTEMLEA approved, zaltenibart deal closed

  Q4 2025 net income $86.5M ($1.22/diluted EPS) vs. net loss $31.4M ($0.54) in Q4 2024; full-year net loss narrowed to $3.4M ($0.05) from $156.8M ($2.70).

• January 7, 2026, 6:59 PM ET other material materiality 0.50 neutral item 2.02

  Omeros reports preliminary cash and short-term investments of $171.5M at year-end 2025

  Preliminary unaudited cash and short-term investments of $171.5M as of Dec 31, 2025.

• December 29, 2025, 6:59 PM ET other material materiality 0.90 positive item 9.01

  FDA approves Omeros' YARTEMLEA as first therapy for TA-TMA; launch set for Jan 2026

  YARTEMLEA (narsoplimab-wuug) approved for adults and children ≥2 years with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).

• December 1, 2025, 6:59 PM ET M&A materiality 0.95 positive item 1.02item 2.01item 9.01 ◈ M&A Transactions

  Omeros closes zaltenibart sale to Novo Nordisk for $240M upfront; repays debt, launches $100M buyback

  Closed sale of zaltenibart to Novo Nordisk for $240M upfront; eligible for up to $2.1B in milestones plus tiered royalties on net sales.

• November 13, 2025, 6:59 PM ET other material materiality 0.90 positive item 2.02item 9.01

  Omeros Q3 net loss narrows; Novo Nordisk deal for zaltenibart up to $2.1B

  Q3 net loss $30.9M ($0.47/sh) vs $32.2M ($0.56/sh) a year ago; adjusted net loss $22.1M ($0.34/sh).

• October 15, 2025, 7:59 PM ET M&A materiality 0.95 positive item 1.01item 8.01item 9.01

  Omeros sells global rights to zaltenibart to Novo Nordisk for up to $2.1B

  Upfront $240M cash plus near-term milestones total $340M; up to $2.1B including development & sales milestones plus tiered royalties.

• August 14, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Omeros Q2 net loss narrows to $25.4M; narsoplimab PDUFA extended to Dec 2025; debt reduced by $80M

  Net loss of $25.4M ($0.43/sh) vs $56.0M ($0.97/sh) a year ago; cash, short-term investments $28.7M at June 30.

• July 25, 2025, 7:59 PM ET other material materiality 0.65 neutral item 8.01item 9.01

  Omeros prices $22M offering, discloses advanced partnership talks, narsoplimab PDUFA now Dec 2025

  Sold 5,365,853 shares at $4.10 each to Polar Asset Management; net proceeds ~$20.3M; expected close July 28.

• July 2, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07

  Omeros shareholders elect directors, approve say-on-pay, ratify Ernst & Young

  Arnold C. Hanish elected Class I director with 16,033,755 for, 1,245,397 against.

• May 16, 2025, 7:59 PM ET other material materiality 0.05 neutral item 9.01

  Omeros files 8-K/A to correct omitted table in Second Supplemental Indenture

  Amendment filed solely to replace Exhibit 4.2 with corrected version including missing table.

• May 15, 2025, 7:59 PM ET earnings materiality 0.85 neutral item 1.01item 2.02item 2.03item 3.02item 8.01item 9.01

  Omeros Q1 net loss $0.58/sh; swaps $70.8M of 2026 notes for 2029 notes at 9.5%

  Net loss $33.5M ($0.58/diluted) vs $37.2M ($0.63) a year ago; OMIDRIA royalties $6.7M on sales of $22.3M.

• May 6, 2025, 7:59 PM ET regulatory materiality 0.75 positive item 8.01item 9.01

  Omeros announces FDA accepts BLA resubmission for narsoplimab in TA-TMA; PDUFA late Sept 2025

  FDA accepted Class 2 resubmission of BLA for narsoplimab for TA-TMA; PDUFA target action date late September 2025.

• March 31, 2025, 7:59 PM ET earnings materiality 0.85 negative item 2.02item 9.01

  Omeros Q4 net loss $31.4M; BLA resubmitted for narsoplimab; PDUFA Sept 2025

  Net loss Q4 2024 $31.4M ($0.54/sh) vs Q3 $32.2M; FY2024 loss $156.8M vs $117.8M prior year.

• February 20, 2025, 6:59 PM ET other material materiality 0.80 positive item 8.01item 9.01

  Omeros reports robust narsoplimab EAP survival data in TA-TMA; BLA resubmission planned Q1 2025

  Combined EAP + pivotal trial vs external control: HR 0.34-0.46, p-values <0.00001 to 0.00002.

• January 16, 2025, 6:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Omeros narsoplimab sensitivity analyses confirm survival benefit; BLA resubmission planned this quarter

  Sensitivity analyses show HR 0.24–0.42 vs external control, p-values 0.0124 to <0.00001, confirming primary endpoint robustness.

• December 19, 2024, 6:59 PM ET other material materiality 0.90 positive item 8.01item 9.01

  Omeros narsoplimab meets TA-TMA pivotal trial primary endpoint; HR 0.32 for survival

  Narsoplimab-treated TA-TMA patients had over 3-fold reduction in risk of death (HR 0.32, 95% CI 0.23-0.44, p<0.00001) vs >100 external control patients.

• November 13, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Omeros Q3 net loss $32.2M; narsoplimab BLA resubmission path cleared after FDA meeting

  Net loss Q3 2024: $32.2M ($0.56/sh) vs $37.8M ($0.60/sh) in Q3 2023; nine-month loss $125.5M.

• August 7, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Omeros Q2 net loss $56M ($0.97/sh) vs $37M; restructures debt with $67M term loan

  Net loss $56.0M ($0.97/sh) vs $37.3M ($0.59); includes $17.6M narsoplimab charge, $21.2M debt repurchase.

• June 12, 2024, 7:59 PM ET leadership materiality 0.40 neutral item 5.02item 5.07 ◈ executive_change ×2

  Omeros CFO Jacobsen retiring June 30; Borges appointed successor

  Michael A. Jacobsen retires as VP Finance, CAO & Treasurer effective June 30, 2024; stays as part-time advisor at $5k/month.

• June 3, 2024, 7:59 PM ET debt materiality 0.85 positive item 1.01item 2.03item 7.01item 8.01item 9.01

  Omeros enters $92.1M term loan, repurchases $118.1M convertible notes at 74.75% of par, extinguishes $51M debt

  New $67.1M initial term loan funded June 3, 2024, plus $25M delayed draw available upon FDA approval of narsoplimab for TA-TMA.

• May 15, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Omeros Q1 net loss $37.2M; cash extends into 2026 after $115.5M royalty deal

  Net loss $37.2M ($0.63/share) vs $33.7M ($0.54) in Q1 2023; loss from cont ops $43.9M vs $39.7M.

• April 1, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Omeros posts Q4 net loss $9.1M, secures $115.5M from OMIDRIA royalty sale

  Q4 2023 net loss $9.1M ($0.15/sh) vs Q3 loss $37.8M; full-year net loss $117.8M ($1.88/sh) vs prior-year net income $47.4M.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.95 · Median 0.75 · Most common event earnings

10 positive 1 negative 12 neutral

source · OMER on sec.gov